CBD products are becoming popular among people of all ages. Here are four stocks to consider.

OTCStockReview.com News Commentary

Cannabis sales are on the rise this year as revenue and profits for many cannabis companies have increased significantly. U.S. legal cannabis sales grew 46% year over year to $17 billion in 2020. The total U.S. economic impact from marijuana sales in 2021 is expected to reach $92 billion – up more than 30% from last year – and upwards of $160 billion in 2025, according to analysis from the MJBizFactbook.

One of the major areas of interest to investors is Cannabidiol, or CBD, which is a component of marijuana that provides users with numerous health benefits without the high of regular marijuana. CBD has proven successful at reducing anxiety, combatting insomnia, and treating chronic pain. Since the 2018 Farm Bill legalized the growth and sale of CBD and Hemp, its popularity has skyrocketed. As marijuana becomes legal in more parts of the United States and North America, oils, creams, moisturizers, chews, isolate, gel caps, concentrate and spa products are just some of the new CBD products that are appearing nationwide. According to a 2019 survey conducted by Consumer Reports 20% of people ages 18-29 use CBD, 16% of people ages 30-49 use CBD, 11% of people ages 50-64 use CBD, and 8% of people age 65 and older use CBD.

Tilray, Inc. (NASDAQ: TLRY), Can B Corp. (OTCQB: CANB), Canopy Growth (NASDAQ: CGC), and Aurora Cannabis (NASDAQ: ACB) are four companies that could have major moves in front of them as investors add cannabis stocks to their portfolios.

Tilray, Inc. (NASDAQ: TLRY) produces high-quality cannabis and cannabis-derived products primarily for global recreational adult-use. Tilray has off and on been the subject of speculation by the players at Wall Street Bets. Tilray offers a broad-based portfolio of brands and adult-use products through its wholly owned subsidiary, High Park Holdings Ltd. The Company also supplies high-quality medical cannabis products to tens of thousands of patients in 17 countries on five continents through its subsidiaries in Australia, Canada, Germany, Latin America and Portugal, and through agreements with established pharmaceutical distributors. Analysts at Cantor Fitzgerald recently upgraded the stock after its merger with Aphria in May. Following the merger, the combined Tilray/Aphria has the largest global geographic footprint in the industry, low-cost production facilities, and a wealth of international growth opportunities.

On July 28, 2021 Tilray reported 2021 fiscal year and fourth quarter results. Net revenue increased 27% to $513 million compared to the prior year net income of $33.6 million. Tilray also posted adjusted EBITDA of $12.3 million, net cash from operating activities of $8.3 million, and positive free cash flow of $3.3 million in Q4. After finalizing the Aphria acquisition, Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, said, "In a very short period of time since our business combination was finalized, we transformed and strengthened Tilray, delivered solid results amid continued COVID-19 lockdowns and restrictions and achieved $35 million in synergies to date – well on our way to delivering $80 million in cost savings over the next 16 months." For more information on Tilray, Inc. visit www.tilray.com

Can B Corp. (OTCQB: CANB) is a Health & Wellness company providing the highest quality hemp derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil and Duramed, as well as licensing of durable medical devices. Can B sets itself apart from other companies by owning the production of its products from end to end. The Company owns Green Grow Farms Inc. which holds licenses to grow and cultivate CBD hemp as well as an extraction and processing registration in the State of New York.

Can B has an R&D laboratory located in its Pure Health Products production facility in Lacey WA. In this facility, Can B creates, develops, tests and produces all of its CBD products, under the highest industry standards which are also 3rd party independent lab tested with the Certificates of Analysis posted on the company’s website. Through its Duramed Division, Can B offers a line of FDA approved medical devices including an ultrasound delivery device which is proven to alleviate joint and muscle pain in surgery and accident patients, aid in recovery time, and reduce swelling. These devices are sold and issued via doctors and the medical community and the company believes these devices are contributing to the reduction in opioid use.

On August 17, 2021 Can B announced it acquired three commercial buildings in Colorado valued at over $5 million for the processing of hemp biomass to CBD consumer products. This gives Can B total supply chain control and chain-of custody for purity, analysis, and certification of its products. The transaction is valued at over $5 million and will feed the Company's Nutraceutical lab in Lacey, Washington, as well as its two isomer (Delta-8- CBD- CBG) operations in Miami, Florida and McMinnville, Tennessee.

The acquisition consists of a 15,000 square foot facility located in Mead, Colorado that converts hemp biomass and unwinterized crude to winterized crude and high-quality CBD crude oil; an 18,000 square foot operation in Fort Morgan, Colorado, which is a former Budweiser facility, that will be used to convert winterized crude to CBD distillate; and an ICS facility located in a 30,000 sq. ft. building in Fort Morgan, CO that will be used to convert distillate to isolate. According to its press release, the Company has yet to execute the leases for these facilities but has negotiated and agreed on the terms with each landlord. For more information on Can B Corp. visit www.canbcorp.com.

Canopy Growth (NASDAQ: CGC) has the largest market cap of any cannabis stock with a market value of around $7.3 billion. Canopy Growth offers product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices. Its global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its color-coded classification system. Through its Tweed and Tokyo Smoke banners, Canopy Growth has built a loyal following. Canopy Growth has a deal in place to buy U.S. cannabis operator Acreage Holdings to grow its U.S. CBD business. Canopy Growth also purchased AV Cannabis Inc., a Toronto company that makes vapes, gummies and pre-rolls, in a bid to build more brand loyalty with customers.

Canopy Growth reported First Quarter fiscal year 2022 financial results on August 6, 2021. Following the release of its first quarter fiscal year 2022 financial results, Canopy Growth hosted an audio webcast with David Klein, CEO and Mike Lee, EVP & CFO at 10:00 AM Eastern Time on August 6, 2021. In February, after the company reported fiscal third-quarter results, CEO David Klein said Canopy could enter the U.S. legal market for THC products "during calendar 2021," provided legislation allowed it. Canopy Growth Corporation, formerly Tweed Marijuana Inc., was founded by Bruce Linton and Chuck Rifici in 2013 and renamed Canopy Growth Corporation in 2015 after a merger with Bedrocan Canada. For more information on Canopy Growth visit www.canopygrowth.com.

Aurora Cannabis (NASDAQ: ACB) is one of the Robinhood investing app's most-held stocks. It also could be a contrarian's dream, since the Company has not had much in the way of good news recently. Aurora Cannabis started the year out around $9.50, ran up to $18.98, and currently trades around $6.93. The main reason for the decline is that, even with massive volume, Aurora keeps diluting its shareholders. According to Motley Fool, after a 1-for-12 reverse split enacted in May 2020, Aurora's share count has increased from 1.3 million shares in mid-2014 to about 198 million shares by March 31, 2021. In May, Aurora announced a $300 million at-the-market offering. To add a little salt to the wound, sales for the third quarter were down by 21% and Aurora posted a loss as lockdowns of Canadian retail stores impacted sales.

In mid-July, Aurora Cannabis announced it had delivered a cannabis shipment worth nearly C$8 million to Israel, which is one of the largest single shipments of cannabis that Israel has received. The Company said the sale is a significant step in advancing the Company's international medical business, which is a key strategic priority for Aurora as a global cannabis company. Aurora said with leadership in both Canada and Europe, it is positioned to be a partner of choice in countries like Israel, where THC recreational markets are expected to be around the corner, and non-THC cannabinoids, such as CBD, are advancing toward legalization. Aurora's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. For more information on Aurora Cannabis visit www.auroramj.com.

DISCLAIMER: OTC Stock Review (OTCSR), which owns and operates OTCStockReview.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. OTCSR is NOT affiliated in any manner with any company mentioned herein. OTCSR and its affiliated companies is a news dissemination solutions provider and are not a registered broker/dealer/analyst/adviser. OTCSR holds no investment licenses and may not sell, offer to sell or offer to buy any security. OTCSR's market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. OTCSR is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed OTCSR was compensated seven thousand five hundred dollars and one hundred thousand shares of CAN B stock for news coverage of current press releases issued by CAN B, Inc. by a non-affiliated third party.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCSR undertakes no obligation to update such statements.

Contact Information:

David Kugelman

(404) 856-9157 Office

(866) 692-6847 Toll Free - U.S. & Canada

This email address is being protected from spambots. You need JavaScript enabled to view it. 

https://www.linkedin.com/in/davidkugelman